FDA approves gene therapy for genetic hearing loss amid systemic gaps in equitable healthcare access and indigenous genetic sovereignty debates
Original framing: “Regeneron wins FDA approval for first gene therapy for genetic hearing loss - Reuters” — Reuters (via Google News)
Scientifically, the FDA’s approval of Regeneron’s gene therapy for genetic hearing loss is based on clinical trial data demonstrating safety and efficacy in a subset of patients with a specific genetic mutation (OTOF). However, the trials may not fully represent diverse populations, as genetic variations across ethnic groups can affect treatment outcomes. Additionally, the long-term effects of gene therapy remain uncertain, and the high cost of such therapies raises questions about scalability and accessibility. The scientific narrative must also consider the ethical implications of germline editing, which could have unintended consequences for future generations.
The FDA’s approval of Regeneron’s gene therapy for genetic hearing loss exemplifies the tension between biomedical innovation and systemic inequities, echoing historical patterns of exploitation in genetic research.
While the scientific breakthrough offers hope for a subset of patients, the narrative obscures the structural barriers that limit its accessibility, particularly for Indigenous and low-income communities who have long faced marginalisation in healthcare. The absence of cross-cultural perspectives—such as Māori communal care models or Ayurvedic holistic approaches—further narrows the scope of potential solutions, reducing complex health challenges to individualised technological fixes. To avoid repeating past injustices, future healthcare systems must prioritise community-led research, equitable access frameworks, and integrative models that bridge traditional and modern medicine. Without these systemic shifts, gene therapies risk becoming another example of innovation that serves the few while leaving the many behind.